In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the risk of substance use disorders (SUDs) among US veterans with type 2 diabetes, emphasizing the veteran population.
Key Findings:
GLP-1 RA initiation was associated with a lower risk for the composite endpoint of all incident SUDs (HR, 0.86), translating to about 7 fewer cases per 1,000 patients over 3 years, with modest absolute risk differences for individual SUDs.
Interpretation:
The findings suggest a potential role for GLP-1 receptor agonists in the context of SUDs, but do not support their use specifically for preventing or treating these disorders; they may inform clinical decisions regarding antihyperglycemic therapy.
Limitations:
The study is observational and subject to possible residual confounding and misclassification, which may affect the reliability of the findings.
Conclusion:
The study indicates that GLP-1 RAs may be relevant in selecting antihyperglycemic therapy for patients with type 2 diabetes at risk for SUDs, but any advantages must be weighed against known adverse effects, emphasizing the need for careful clinical consideration.
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
